All In Biotech

Drug Trial Radar · NCT04516564

A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, First-In-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AK119 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Feb 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

29

Actual

Start

Sep 28, 2020

Primary completion

May 4, 2021

Study completion Jun 21, 2021

Sponsor

Lead sponsor
Akesobio Australia Pty LtdIndustry
Sponsor type
Industry
First posted
Aug 18, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a first-in-human (FIH), Phase 1, single-center, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, PK and immunogenicity of AK119, a humanized monoclonal antibody targeting the CD73. The study will consist of 4 cohorts of healthy subjects. Eight subjects will be enrolled per cohort, randomized in a 3:1 ratio to receive a single dose of either the active drug AK119 (N=6) or matching placebo (N=2). Approximately 32 subjects (24 receiving active drug and 8 receiving placebo) will participate in this study.

Conditions

  • Coronavirus Disease 2019 (COVID-19)

Interventions

  • AK119Drug

    Single dose of AK119 is administered via intravenous infusion to healthy subjects

  • PlaceboDrug

    Single dose of placebo is administered via intravenous infusion to healthy subjects

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent AEsTime frame: From signing of informed consent till end of study (approximately 64 days postdose)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Christchurch Clinical Studies Trust

    Christchurch, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.